| Literature DB >> 33753738 |
Jun Wu1,2, Boyun Liang1,2, Cunrong Chen3, Hua Wang1,2, Yaohui Fang4, Shu Shen4, Xiaoli Yang1,2, Baoju Wang1,2, Liangkai Chen5,6, Qi Chen7, Yang Wu7, Jia Liu1,2, Xuecheng Yang1,2, Wei Li1,2, Bin Zhu1,2, Wenqing Zhou1,2, Huan Wang1,2, Sumeng Li1,2, Sihong Lu1,2, Di Liu8, Huadong Li9, Adalbert Krawczyk10, Mengji Lu2,11, Dongliang Yang1,2, Fei Deng12, Ulf Dittmer13,14, Mirko Trilling15,16, Xin Zheng17,18.
Abstract
Long-term antibody responses and neutralizing activities in response to SARS-CoV-2 infection are not yet clear. Here we quantify immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) or the nucleocapsid (N) protein, and neutralizing antibodies during a period of 6 months from COVID-19 disease onset in 349 symptomatic COVID-19 patients who were among the first be infected world-wide. The positivity rate and magnitude of IgM-S and IgG-N responses increase rapidly. High levels of IgM-S/N and IgG-S/N at 2-3 weeks after disease onset are associated with virus control and IgG-S titers correlate closely with the capacity to neutralize SARS-CoV-2. Although specific IgM-S/N become undetectable 12 weeks after disease onset in most patients, IgG-S/N titers have an intermediate contraction phase, but stabilize at relatively high levels over the 6 month observation period. At late time points, the positivity rates for binding and neutralizing SARS-CoV-2-specific antibodies are still >70%. These data indicate sustained humoral immunity in recovered patients who had symptomatic COVID-19, suggesting prolonged immunity.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33753738 DOI： 10.1038/s41467-021-22034-1
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919